On May 16, 2018 Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that a second U.S. site, located in Lubbock, Texas, has qualified for its clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia ("AML") (Press release, Moleculin, MAY 16, 2018, View Source [SID1234526711]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
UMC Southwest Cancer Center has now qualified as the second U.S. site for Moleculin’s clinical trial of Annamycin. Dr. Sanjay Awasthi, Division Chief of Hematology/Oncology at Texas Tech University will serve as the site’s Principal Investigator.
"We are extremely pleased to announce our second site, as every new site opened for this clinical trial expands our ability to recruit patients and moves us one step closer to generating the data we are all eager to see," commented Walter Klemp, Moleculin’s Chairman and CEO. "Annamycin represents a unique treatment opportunity to address a critical unmet need in relapsed/refractory AML. Currently approved first-line therapy fails to help a majority of AML patients because of multidrug resistance and the limitations presented by the inherent damage those drugs can do to a patient’s heart ("cardiotoxicity"). Unfortunately, there is no effective second-line therapy for a majority of those patients. Preclinical studies have shown that Annamycin has an ability to avoid the multidrug resistance mechanisms that defeat currently approved AML drugs and is designed to have little to no cardiotoxicity. We hope to reproduce this data in our current Phase I/II clinical study and that Annamycin can finally provide a second-line treatment option for the majority of AML patients."
UMC Southwest Cancer Center
The UMC Southwest Cancer Center in Lubbock, Texas is a nationally recognized leader in the fight against cancer. Their multi-disciplinary approach combines the expertise of Texas Tech Physicians with UMC’s compassionate care and technological advancements. Comprehensive cancer treatment and care is available in one facility, close to home.